Xie Xina, Ph.D. in Biochemistry and Molecular Biology, Associate Researcher, Shenzhen Reserve-level High-caliber Talent

Dr. Xie Xina received her medical bachelor's degree from Sun Yat-sen University in June 2009. She then obtained her master's degree in Pathology and Pathophysiology and her Ph.D. in Biochemistry and Molecular Biology from Shantou University Medical College. In October 2017, she began her postdoctoral research at Shenzhen Second People's Hospital. After completing her postdoctoral research in August 2019, she joined the Shenzhen Second People's Hospital (Shenzhen Institute of Translational Medicine) as an assistant researcher and later an associate researcher. As an academic backbone of the Guangdong Provincial Key Laboratory of Urogenital Tumor System and Synthetic Biology, she primarily focuses on the epigenetic research of the pathogenesis of metabolic diseases and tumors.

To date, Dr. Xie has published 11 SCI papers in renowned journals such as Circulation Research, Clinical Science, Cell Death & Disease, and International Journal of Biological Sciences as the first author, corresponding author, or co-first/co-corresponding author, with a total impact factor of approximately 79.858 and the highest single paper impact factor of 23.213. She has completed or is currently leading five research projects, including the National Natural Science Foundation Youth Fund, General Program, China Postdoctoral Fund, and Shenzhen Science and Technology Innovation Foundation Basic Research Free Exploration and General Program, with a total funding of 1.48 million yuan. She has also been granted one national invention patent.

Education:

2005.9-2009.6:Sun Yat-sen University, Nursing, Bachelor of Medicine

2009.9-2012.6:Shantou University Medical College, Pathology and Pathophysiology, Master of Medicine

2013.9-2017.6:Shantou University Medical College, Biochemistry and Molecular Biology, Doctor of Science

Epigenetic Research on the Pathogenesis of Diseases such as Sexual Disorders and Tumors

Epigenetic dysregulation is widespread in tumors and various other clinical diseases. With the development of clinical trials for various epigenetic drugs, the combination of epigenetic drugs with chemotherapy and immunotherapy has become a new trend in recent years, providing more possibilities for the treatment of tumors and other diseases.

Enhancers are crucial gene regulatory elements within the cell nucleus. A single enhancer can simultaneously regulate multiple proximal and/or distal genes with similar functions, forming a broad and intricate epigenetic regulatory network that expands its functional scope. An increasing number of enhancers have been confirmed to play significant roles in cancer, and targeting enhancers is expected to become a new strategy for the treatment of tumors and other diseases.

Dr. Xie Xina focuses on enhancers with potential developmental prospects and application value, aiming to construct a comprehensive epigenetic regulatory network of oncogenic enhancers that trigger disease progression. This research lays the foundation and provides preclinical evidence for drug development and clinical therapy based on enhancers.

Research Projects:

National Natural Science Foundation of China (General Program):Epigenetic study on the regulation of colorectal cancer development by specifically activated enhancers, 580,000 RMB, ongoing.

Shenzhen Science and Technology Innovation Commission Basic Research Program:Mechanism of the enhancer and eRNA of the NR4A1 gene in the development and metastasis of colorectal cancer, 300,000 RMB, ongoing.

Shenzhen Science and Technology Innovation Basic Research Free Exploration Program:Mechanistic study of LncRNA NR4A1-AS1 regulation of NR4A1 in colorectal cancer, 320,000 RMB, ongoing.

National Natural Science Youth Fund:Epigenetic study on the transcriptional regulation of NR4A1/NUR77 by homocysteine in hepatocytes, 230,000 RMB, completed.

63rd Batch of China Postdoctoral Fund General Program:Mechanistic study of long non-coding RNA NR4A1-AS regulation of NR4A1 in colorectal cancer, 50,000 RMB, completed.

（1）Zhang D^＃, Xie X^＃, Chen Y, Hammock BD, Kong W, Zhu Y＊. Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Circ Res. 2012;110: 808-817. (^＃并列第一作者, IF:23.213)

（2） Xie X, Song X, Yuan S, Cai H, Chen Y, Chang X, Liang B^＊, Huang D^＊. Histone acetylation regulates orphan nuclear receptor NR4A1 expression in hypercholesterolaemia. Clinical Science (Lond). 2015;129(12):1151-1161.（IF: 6.876）

（3） Xie X, Lin J, Liu J, Huang M, Zhong Y, Liang B, Song X, Gu S, Chang X, Huang D, Tang A^＊. A novel lncRNA NR4A1AS upregulates orphan nuclear receptor NR4A1 expression by blocking UPF1-mediated mRNA destabilization in colorectal cancer. Clinical Science. 2019;133: 1457-1473. (IF: 6.876)

（4） Huang M^＃, Xie X^＃, Song X, Gu S, Chang X, Su T, Liang B^＊, Huang D^＊. MiR-506 suppresses colorectal cancer development by inhibiting orphan nuclear receptor NR4A1 expression. Journal of Cancer. 2019; 10(15): 3560-3570. (^＃并列第一作者, IF: 4.478)

（5） Liang H^＃, Xie X^＃, Song X, Huang M, Su T, Chang X, Liang B^＊, Huang D^＊. Orphan nuclear receptor NR4A1 suppresses hyperhomocysteinemia-induced hepatic steatosis in vitro and in vivo. FEBS Lett. 2019; 593(10):1061-1071. (＃并列第一作者, IF: 3.864)

（6）Fan X^＃＊, Xie X^＃, Yang M, Wang Y, Wu H, Deng T, Weng X, Wei W, Nie G^＊. YBX3 mediates the metastasis of nasopharyngeal carcinoma via PI3K/AKT signaling. Frontiers in Oncology. 2021,17;11:617621. (^＃并列第一作者, IF:5.738)

（7）Xie X^＃, Lin J^＃, Fan X^＃, Zhong Y, Chen Y, Liu K, Ren Y, Chen X, Lai D, Li X, Li Z^＊, Tang A^＊. LncRNA CDKN2B-AS1 stabilized by IGF2BP3 drives the malignancy of renal clear cell carcinoma through epigenetically activating NUF2 transcription. Cell Death Dis. 2021, 12(2): 201. ( IF: 9.685)

（8）Lin J^＃, Chen X^＃, Yu H, Min S, Chen Y, Li Z^＊, Xie X^＊. NUF2 Drives Clear Cell Renal Cell Carcinoma by Activating HMGA2 Transcription through KDM2A-mediated H3K36me2 Demethylation. Int. J. Biol. Sci. 2022, 18(9): 3621-3635 (*通讯作者, IF:10.75)